[1] Fast-track:ending the AIDS epidemic by 2030[EB/OL].(2014-11-24)[2024-01-08].https://www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014report_en.pdf.
[2] 国家卫生计生委办公厅.国家卫生计生委办公厅关于调整艾滋病免费抗病毒治疗标准的通知.(2016-06-08)[2024-01-08].http://www.nhc.gov.cn/yzygj/s3593/201606/0b0fa78e10dc41328e842b1bf9cd433e.
[3] 中国疾病预防控制中心性病艾滋病预防控制中心.全国艾滋病性病丙肝综合防治数据信息年报[M].2022.
[4] 李敬云.HIV耐药的现状、挑战与应对[J].传染病信息,2019,32(6):490-495.
[5] Oroz M,Begovac J,Planini A,et al.Analysis of HIV-1 diversity,primary drug resistance and transmission networks in Croatia[J].Sci Rep,2019,9(1):17307.
[6] Schultze A,Phillips AN,Paredes R,et al.HIV resistance testing and detected drug resistance in Europe[J].AIDS,2015,29(11):1379-1389.
[7] Giacomelli A,Pezzati L,Rusconi S.The crosstalk between antiretrovirals pharmacology and HIV drug resistance[J].Expert Rev Clin Pharmacol,2020,13(7):739-760.
[8] World Health Organization.Consolidated guidelines on HIV prevention,testing,treatment,service delivery and monitoring: recommendations for a public health approach[EB/OL].(2021-07)[2024-01-08].https://apps.who.int/iris/handle/10665/342899.
[9] Chen H,Hao J,Hu J,et al.Pretreatment HIV drug resistance and the molecular transmission network among HIV-positive individuals in China in 2022:multicenter observational study[J].JMIR Public Health Surveill,2023,9:e50894.
[10] Zhao S,Feng Y,Hu J,et al.Prevalence of Transmitted HIV drug resistance in antiretroviral treatment naïve newly diagnosed individuals in China[J].Sci Rep,2018,8(1):12273.
[11] Kang RH,Liang SJ,Ma YL,et al.Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China,2017[J].Infect Dis Poverty,2020,9(1):54.
[12] Liao L,Xing H,Shang H,et al.The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China[J].J Acquir Immune Defic Syndr,2010,53(Suppl 1):S10-S14.
[13] 刘大锦,冯孟贤,刘民.中国未接受抗病毒治疗的人类免疫缺陷病毒/获得性免疫缺陷综合征(HIV/AIDS)人群HIV原发耐药的Meta分析[J].北京大学学报(医学版),2015,47(3):474-482.
[14] World Health Organization.(2019).HIV drug resistance report 2019.World Health Organization.(2019-07-17)[2024-01-08].https://apps.who.int/iris/handle/10665/325891.
[15] Zhao B,Song W,Kang M,et al.Molecular network analysis reveals transmission of HIV-1 drug-resistant strains among newly diagnosed HIV-1 infections in a moderately HIV endemic city in China[J].Front Microbiol,2022,12:797771.
[16] Ye J,Hao M,Xing H,et al.Transmitted HIV drug resistance among individuals with newly diagnosed HIV infection:a multicenter observational study[J].AIDS,2020,34(4):609-619.
[17] Zhang D,Zheng C,Li H,et al.Molecular surveillance of HIV-1 newly diagnosed infections in Shenzhen,China from 2011 to 2018[J].J Infect,2021,83(1):76-83.
[18] Hao J,Zheng S,Gan M,et al.Changing proportions of HIV-1 subtypes and transmitted drug resistance among newly diagnosed HIV/AIDS individuals - China,2015 and 2018[J].China CDC Wkly,2021,3(53):1133-1138.
[19] Lan Y,Li L,Xin R,et al.Drug resistance to integrase strand-transfer inhibitors among HIV-1-infected adults in Guangdong,China[J].Pathogens,2022,11(11):1321.
[20] Li D,Chen H,Li H,et al.HIV-1 pretreatment drug resistance and genetic transmission network in the southwest border region of China[J].BMC Infect Dis,2022,22(1):741.
[21] Zuo L,Liu K,Liu H,et al.Trend of HIV-1 drug resistance in China:a systematic review and meta-analysis of data accumulated over 17 years (2001—2017)[J].EClinicalMedicine,2020,18:100238.
[22] Zazzi M,Hu H,Prosperi M.The global burden of HIV-1 drug resistance in the past 20 years[J].PeerJ,2018,6:e4848.
[23] Wang Z,Zhang M,Zhang R,et al.Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai,China[J].BMC Infect Dis,2019,19(1):313.
[24] Xu X,Luo L,Song C,et al.Survey of pretreatment HIV drug resistance and the genetic transmission networks among HIV-positive individuals in southwestern China,2014—2020[J].BMC Infect Dis,2021,21(1):1153.
[25] Liu L,Dong A,Liao L,et al.Survey of pretreatment HIV drug resistance and genetic transmission network analysis among HIV patients in a high drug-use area of southwest China[J].Curr HIV Res,2019,17(6):441-451.
[26] Yuan H,Liu Z,Wu X,et al.Prevalence of transmitted HIV-1 drug resistance among treatment-naive individuals in China,2000—2016[J].Arch Virol,2021,166(9):2451-2460.
[27] Ndashimye E,Arts EJ.Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I:Impact in low-and middle-income settings[J].Int J Infect Dis,2021,105:298-303.
[28] Wei X,Ghosh SK,Taylor ME,et al.Viral dynamics in human immunodeficiency virus type 1 infection[J].Nature,1995,373(6510):117-122.
[29] Weber J,Chakraborty B,Weberova J,et al.Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation[J].J Clin Microbiol,2005,43(3):1395-1400.
[30] Bandyopadhyay A,Chaurasia RC,Palepu S,et al.A study of adherence to antiretroviral therapy in a tertiary care hospital at Allahabad,India[J].Indian J Sex Transm Dis AIDS,2019,40(1):46-50.
[31] Sohler N,Slawek D,Earnshaw V,et al.Drug use and HIV medication adherence in people living with HIV[J].Subst Abus,2021,42(3):310-316.
[32] Hillis A,Germain J,Hope V,et al.Pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men (MSM):a scoping review on PrEP service delivery and programming[J].AIDS Behav,2020,24(11):3056-3070.
[33] Abbas UL,Hood G,Wetzel AW,et al.Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP)[J].PLoS One,2011,6(4):e18165.
[34] Baeten JM,Donnell D,Ndase P,et al.Antiretroviral prophylaxis for HIV prevention in heterosexual men and women[J].N Engl J Med,2012,367(5):399-410.
[35] Elliott T,Sanders EJ,Doherty M,et al.Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP),post-exposure prophylaxis (PEP),test and start and acute HIV infection:a scoping review[J].J Int AIDS Soc,2019,22(12):e25419.
[36] Liegler T,Abdel-Mohsen M,Bentley LG,et al.HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial[J].J Infect Dis,2014,210(8):1217-1227.
[37] Kosakovsky Pond SL,Weaver S,Leigh Brown AJ,et al.HIV-TRACE (TRAnsmission cluster engine):a tool for large scale molecular epidemiology of HIV-1 and other rapidly evolving pathogens[J].Mol Biol Evol,2018,35(7):1812-1819.
[38] Kostaki EG,Limnaios S,Roussos S,et al.Validation of molecular clock inferred HIV infection ages:evidence for accurate estimation of infection dates[J].Infect Genet Evol,2021,91:104799.
[39] Wertheim JO,Oster AM,Switzer WM,et al.Natural selection favoring more transmissible HIV detected in United States molecular transmission network[J].Nat Commun,2019,10(1):5788.
[40] Wang X,Liu X,Li F,et al.Epidemiological surveillance of HIV-1 transmitted drug resistance among newly diagnosed individuals in Shijiazhuang,Northern China,2014-2015[J].PLoS One,2018,13(6):e0198005.
[41] Castro H,Pillay D,Cane P,et al.Persistence of HIV-1 transmitted drug resistance mutations[J].J Infect Dis,2013,208(9):1459-1463.
[42] Bandera A,Gori A,Clerici M,et al.Phylogenies in ART:HIV reservoirs,HIV latency and drug resistance[J].Curr Opin Pharmacol,2019,48:24-32.
[43] Devereux HL,Youle M,Johnson MA,et al.Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy[J].AIDS,1999,13(18):F123-F127.
[44] Verhofstede C,Wanzeele FV,Van Der Gucht B,et al.Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype[J].AIDS,1999,13(18):2541-2546.
[45] Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV [EB/OL].(2023-11-06)[2024-01-08]https://clinicalinfo.hiv.gov/en/guidelines.
[46] 陈宏利,周业胜,郝静静,等.抗病毒治疗前耐药对HIV感染者治疗3年后病毒学应答的影响[J].中华流行病学杂志,2022,43(11):1778-1783.
[47] Wittkop L,Günthard HF,de Wolf F,et al.Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project):a European multicohort study[J].Lancet Infect Dis,2011,11(5):363-371.
[48] Hamers RL,Schuurman R,Sigaloff KCE,et al.Effect of pretreatment HIV-1 drug resistance on immunological,virological,and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa:a multicentre cohort study[J].Lancet Infect Dis,2012,12(4):307-317.
[49] McCluskey SM,Siedner MJ,Marconi VC.Management of virologic failure and HIV drug resistance[J].Infect Dis Clin North Am,2019,33(3):707-742.
[50] Chen H,Hu J,Song C,et al.Molecular transmission network of pretreatment drug resistance among human immunodeficiency virus-positive individuals and the impact of virological failure on those who received antiretroviral therapy in China[J].Front Med,2022,9:965836.
[51] Siedner MJ,Moorhouse MA,Simmons B,et al.Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase[J].Nat Commun,2020,11(1):5922.
[52] Parikh UM,McCormick K,van Zyl G,et al.Future technologies for monitoring HIV drug resistance and cure[J].Curr Opin HIV AIDS,2017,12(2):182-189.